BAXTER INTL INC shareholders Q3 2023

BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 885 filers reported holding BAXTER INTL INC in Q3 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.

BAXTER INTL INC shareholders Q3 2023
NameSharesValueWeighting ↓
JONES ROAD CAPITAL MANAGEMENT, L.P. 200,000$7,548,0006.60%
BOONE CAPITAL MANAGEMENT LLC 469,405$17,715,3455.59%
Soditic Asset Management LLP 186,920$7,054,3615.43%
JONES ROAD CAPITAL MANAGEMENT, L.P. 131,000$4,943,9404.32%
Camber Capital Management LP 3,000,000$113,2203.73%
Carmignac Gestion 4,848,773$182,991,7183.36%
SHAPIRO CAPITAL MANAGEMENT LLC 3,028,799$114,306,8743.33%
Hillman Capital Management, Inc. 219,248$8,274,4203.19%
Cincinnati Specialty Underwriters Insurance CO 201,500$7,604,6102.90%
Callodine Capital Management, LP 265,000$10,001,1002.79%
PVG ASSET MANAGEMENT CORP 10,147$382,9472.61%
PENSIOENFONDS RAIL & OV 1,090,925$39,1862.60%
Sivik Global Healthcare LLC 125,000$4,7182.38%
Magnetar Financial LLC 2,421,802$91,398,8072.33%
STONERIDGE INVESTMENT PARTNERS LLC 129,323$4,8812.30%
PointState Capital LP 3,515,709$132,682,8582.26%
PLATINUM INVESTMENT MANAGEMENT LTD 1,460,972$55,137,0832.15%
MAVERICK CAPITAL LTD 2,219,689$83,771,0631.89%
SECTOR GAMMA AS 193,243$7,292,9911.86%
Orbimed Advisors 2,239,900$84,533,8261.80%
About BAXTER INTL INC

Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.

Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.

Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.

Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.

Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BAXTER INTL INC's shareholders in Q3 2023. To view BAXTER INTL INC's shareholder history, click here.